TNF receptor superfamily member 19Genealiases: TAJ · TAJ-alpha · TRADE · TROY
Q-omics provides the consensus-scored TNFRSF19 profile across patient tissues and cancer cell-line models. TNFRSF19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TNFRSF19 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, TNFRSF19 RNA expression shows 18,828 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where TNFRSF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF19 survival associations across molecular data types. TNFRSF19 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF19 RNA expression–survival associations across cancer types. High TNFRSF19 expression shows unfavorable associations in UVM, ACC, MESO and LGG, but favorable associations in KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TNFRSF19 RNA expression.
This table summarizes TNFRSF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF19 shows lower tumor expression in LUAD, KICH, LUSC, THCA and HNSC and higher tumor expression in LIHC. The LUAD box plot shows higher TNFRSF19 RNA expression in normal versus tumor tissue (log2 FC = −1.844, t-test p < 0.001).
This table shows molecular features associated with TNFRSF19 in patient tissues and cancer cell lines. In patient samples, TNFRSF19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
